Post-Exposure Prophylaxis with Xofluza

Indications and Administration

The American Academy of Pediatrics and other guidelines recommend Xofluza prophylaxis for asymptomatic individuals at very high risk of complications, such as severely immunocompromised persons, after household exposure 1, 2
Unvaccinated household contacts of persons at very high risk of complications from influenza should receive Xofluza prophylaxis 1, 2
High-risk children who are unvaccinated, recently vaccinated, or immunocompromised with potentially inadequate vaccine response may benefit from Xofluza prophylaxis 3

Xofluza is contraindicated in pregnant or breastfeeding women, and severely immunocompromised patients as monotherapy due to concerns about resistance emergence 3, 4
Patients with known hypersensitivity to baloxavir marboxil should not receive Xofluza 3, 4

Neuraminidase inhibitors, such as oseltamivir or zanamivir, remain the primary recommended agents for post-exposure prophylaxis in most guidelines 1, 5, 2
Oseltamivir prophylaxis requires 75 mg once daily for 7-10 days after exposure 6, 5

If a person receiving prophylaxis develops symptoms, immediately test for influenza and switch to full antiviral treatment dosing, preferably with an antiviral drug with a different resistance profile 1, 2